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Novelty and Impact
While observational studies have suggested an association between blood cholesterol levels and
colorectal cancer (CRC), they do not establish causality and may be influenced by confounding
factors. Here we use Mendelian randomisation using genetic instrumental variables to provide
evidence for a causal link between blood cholesterol levels and colorectal cancer. Thus, reducing
hyperlipidaemia is an important target for primary prevention of CRC in the population.
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ABSTRACT
While elevated blood cholesterol has been associated with an increased risk of colorectal cancer
(CRC) in observational studies, causality is uncertain. Here we apply a Mendelian randomisation
(MR) analysis to examine the potential causal relationship between lipid traits and CRC risk. We
used single nucleotide polymorphisms (SNPs) associated with blood levels of total cholesterol (TC),
triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) as instrumental
variables (IV). We calculated MR estimates for each risk factor with CRC using SNP-CRC
associations from 9,254 cases and 18,386 controls. Genetically predicted higher TC was associated
with an elevated risk of CRC (odds ratios (OR) per unit SD increase = 1.46, 95% confidence interval
[CI]: 1.20-1.79, P=1.68x10-4). The pooled ORs for LDL, HDL, and TG were 1.05 (95% CI: 0.92-1.18,
P=0.49), 0.94 (95% CI: 0.84-1.05, P= 0.27), and 0.98 (95% CI: 0.85-1.12, P=0.75) respectively. A
genetic risk score for 3-hydoxy-3-methylglutaryl-coenzyme A reductase (HMGCR) to mimic the
effects of statin therapy was associated with a reduced CRC risk (OR=0.69, 95% CI: 0.49-0.99,
P=0.046). This study supports a causal relationship between higher levels of TC with CRC risk, and
a further rationale for implementing public health strategies to reduce the prevalence of
hyperlipidaemia.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer diagnosed in economically developed
countries1. The mortality rate from CRC has been declining over the last twenty years as a
consequence of improved medical care and probably through the introduction of population
screening programs for the early detection of tumours2-4. Despite this improvement in patient
outcome, it is still important to understand the risk factors for CRC in order to inform public health
policy.
A number of factors influenced by lifestyle have been reported to be associated with the
development of CRC in epidemiological observational studies, including a positive correlation with
circulating levels of plasma cholesterol and other components of the lipid profile5, 6. It is, however,
unclear from these studies if findings reflect a causal relationship or are simply a consequence of
confounding by factors common to the aetiology of both CRC and hyperlipidaemia (e.g. common
dietary factors) or reverse causality. Because lipid levels can be modified by lifestyle and treatment
with statins, deciphering the basis for the association should be informative in formulating and
optimizing prevention programs for CRC.
Evidence that statin use will effect a reduction in CRC is highly controversial7, 8. Although an
analysis of The Health Improvement Network (THIN) database found that statin usage was
associated with reduced CRC (long term usage: odds ratio [OR] = 0.95, 95% confidence interval
[CI]: 0.91-0.99; short term usage: OR= 0.92, 95% CI: 0.85-0.99); no difference was shown between
continued versus discontinued therapy, suggesting indication bias8. Moreover a recent meta-
analysis of data from eight randomized controlled trials (RCTs) failed to demonstrate a beneficial
effect which was statistically significant (relative risk = 0.89, 95% CI: 0.74-1.07)9. Each of these
RCTs, however have the same limitations of short follow-up time, few CRC cases, and
ascertainment of CRC as a secondary outcome.
Mendelian randomisation (MR) provides a useful complement to the traditional epidemiological
study10. This strategy makes use of genetic variants that are robustly associated with traits of
interest, in this case lipid traits - total cholesterol (TC), low-density lipoprotein (LDL), high-density 
lipoprotein (HDL), and triglyceride (TG) - as instrumental variables (IV) to infer whether
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associations between exposure and disease are causal. The use of genetic variants as IV to proxy
modifiable exposure therefore avoids confounding by environmental factors, can be reflective of
life-long exposure (propensity), and is not be subject to reverse causality. The strength of the IV in
MR is important for power, but weak instruments can also lead to inconsistent instrumental
variables estimators. Hence using a genetic score derived from a combination of single nucleotide
polymorphisms (SNPs), which collectively explains more of the variance in the risk factor, mitigates
against weak instrument bias thereby increasing study power.
Genetics scores derived from multiple SNPs for lipid traits have been used in MR studies to
investigate associations between blood lipids and coronary heart disease11, and most recently
prostate cancer12. Here we have employed MR to examine the impact of lipid traits on the risk of
developing CRC.
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METHODS
Colorectal cancer datasets
We investigated the relationship between genetic risk scores for lipid traits and CRC risk using data
from seven previously reported genome-wide association studies (GWAS) of CRC13 (Table 1).
Briefly, these GWAS were all based on individuals with European ancestry and comprise: CCFR1,
CCFR2, COIN, FINLAND, UK1, Scotland1 and VQ58. All studies were approved by their respective
institutional review boards and conducted with appropriate ethical criteria in each country and in
accordance with the Declaration of Helsinki. Comprehensive details on the cases and controls are
available in previously published work13-16.
Genotyping data
Details of the genotyping and quality control of the seven CRC GWAS have been previously
published13. Briefly, we excluded SNPs with a minor allele frequency of <1%, low call rate <95%,
SNPs violating Hardy-Weinberg equilibrium, and individuals with non-European ancestry as
assessed using HapMap v2 reference data17. Imputation of untyped SNP genotypes was performed
using IMPUTEv2 software18 using a merged reference panel consisting of Sequencing Initiative
Suomi (for the FINLAND data) or UK10K (for the remaining data) in addition to 1000 Genomes
Project data. Poorly imputed SNPs (i.e. INFO score of <0.8) were excluded. Summary statistics from
the seven GWAS were used to calculate the ORs for lipid-related SNPs.
Gene variants used to construct genetic risk scores
Genetic risk scores as IVs for circulating lipid fractions were developed from SNPs previously
identified by the Global Lipids Genetics Consortium (GLGC)19. Median and range of standard
deviations of lipid trait measurements in European cohorts of the Global Lipids Genetics
Consortium are shown in Supplementary Table 1. We considered only SNPs associated at
genome-wide significance (i.e. P ≤ 5.0x10-8) and restricted to individuals with European Ancestry.
To avoid co-linearity between SNPs, we excluded SNPs that were correlated (i.e. r2 value ≥ 0.01), 
only considering the SNP with the strongest effect on the lipid trait for inclusion in genetic risk
scores. Pairwise r2 values were calculated using PLINK v1.90 utilising samples of European ancestry
from the 1000 Genomes and UK10K sequencing projects (Supplementary Data). This resulted in
58 SNPs for HDL, 29 SNPs for LDL, 26 SNPs for TG, and 38 SNPs for TC (Supplementary Table 2).
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Because lipid traits share common genetic variants, in addition to calculating an ‘unrestricted
allele score’ that included all SNPs associated with the lipid trait, we also calculated a ‘restricted
allele score’ as per Holmes et al 11 based on SNPs exclusively associated with HDL (n=43), LDL
(n=9), or TG (n=14) to make them as specific as possible (Supplementary Table 3). Risk alleles
were those that were positively associated with TC, LDL and TG or negatively associated with HDL
levels. For all identified SNPs, we recovered the chromosome positions, the risk alleles, association
estimates and standard errors.
Statistical analysis
We performed MR analysis to assess the association between TC, LDL, HDL, TG and CRC using
summary statistics as described Burgess et al. (2015) 20. The combined ratio estimate ( ) of all
SNPs associated with each lipid trait on CRC was calculated under a fixed-effects model:
Xk corresponds to the association between SNP k with the lipid trait and Yk is the association
between SNP k and CRC risk with standard error The standard error of the combined ratio
estimate is given by:
With the statistics generated by following these calculations on the seven different cohorts in the
CRC data, we performed a meta-analysis under a fixed-effects model to derive the final ORs and
confidence intervals.
A key assumption for this MR analysis is there is no pleiotropism (i.e. a gene influencing multiple
traits) between the genes influencing CRC and the lipid traits under study. Therefore, before
performing the MR analysis, we performed LD regression to test for global evidence of pleiotropy
as per Bulik-Sullivan et al. (2015) 21, 22, and subsequently implemented an MR-Egger regression to
examine for violation of the standard IV assumptions in our analysis 23.
For each statistical test we considered a global significance level of P≤0.05 as being satisfactory to 
derive conclusions. To assess the robustness of our conclusions, we imposed a conservative
Bonferroni-corrected significance threshold of 0.0125 (i.e. 0.05/4 lipid traits). We deemed a P-
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value > 0.05 as non-significant (i.e. no association), a P-value ≤0.05 as evidence for a potential 
causal association, and a P-value ≤0.0125 as significant evidence for a causal association. All 
statistical analyses were undertaken using R software (Version 2.14.1).
The power of a MR investigation depends greatly on the proportion of variance in the risk factor
that is explained by the IV. We estimated study power using the methodology of Burgess (2014) 24,
utilizing published estimates of the heritability of lipid trait associated IV SNPs 19 and the reported
effect of each trait on CRC risk in epidemiological studies 8.
In a subsidiary analysis we constructed a genetic risk score for 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR) using rs12916, rs17238484, rs5909, rs2303152, rs10066707 and rs2006760.
These specific SNPs have previously been used to mimic statin intervention to estimate a causal
association of statin use and coronary heart disease and diabetes 25.
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RESULTS
Using LD regression, we found no evidence for global pleiotropism (i.e. shared genetic
components) between CRC and any of the lipid traits under investigation (Table 2). Following on
from these observations we performed MR-Egger regression tests to explicitly examine for
infringement of the standard instrumental variable assumptions in our MR analysis. We did not
find evidence of any violation in respect to TC, LDL, HDL or TG (Table 2, Supplementary Figure 1).
In view of the totality of these findings we were reassured of the validity of our MR-based analysis
to infer whether the relation between exposures and CRC were likely to be causal.
The associations of each unrestricted allele score for respective target lipid traits are shown in
Figure 1. A positive correlation between variants associated with higher risk levels of TC and CRC
was observed. The pooled OR meta-analysis for CRC by TC, estimated in IV analysis using the allele
score was 1.46 per genetically instrumented SD increase in TC (95% CI: 1.20-1.79, P = 1.68 x 10-4,
test for heterogeneity between studies I2 = 6%, Phet = 0.38).
The strongest reported SNP association for TC levels was provided by rs10401969 (CILP2) and
rs12916 (HMGCR)19. To examine if the correlation between TC and CRC risk was primarily driven
by these variants, we performed a sensitivity analysis excluding rs10401969 and rs12916.
Omission of these two SNPs from the MR analysis did not appreciably affect our MR findings with
results remaining significant (OR = 1.69, 95% CI: 1.25-2.28, P = 6.76 x 10-4). Albeit not significant,
there was some support for a positive association with LDL (OR = 1.05, 95% CI: 0.92-1.18, P = 0.49)
and CRC risk, and a negative association between HDL (OR = 0.94, 95% CI: 0.84-1.05, P = 0.27) and
CRC risk.
Following on from these analyses, we performed a MR based analysis of LDL, HDL and TG using
genetic scores derived from restricted sets of SNPs. As with the unrestricted analysis, no significant
causal effect for each of these lipid traits was observed (Supplementary Figure 2).
Finally, genetically predicted lowered TC using the HMGCR genetic risk score was associated with
43% reduction in CRC (OR=0.69, 95% CI: 0.49-0.99, P=0.046, Phet= I2=56%).
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DISCUSSION
The present study strengthens a causal inference between circulating levels of TC and risk of
developing CRC that is independent of known confounding effects. The positive correlation
between the IV for TC and CRC risk, remained significant even after imposing a Bonferroni-
correction to account for multiple testing. It is noteworthy that none of the IV SNPs for TC also
represent IVs for obesity26, supporting an independent relationship between TC and CRC. As
illustrated here and in previously studies of obesity and CRC 27, 28, insulin levels and uterine cancer
29, and lipid levels and coronary heart disease 30 MR provides an attractive means of establishing
causal associations. In addition to demonstrating an association between TC and CRC risk we
found that genetic variants that mimic the effect of HMGCR inhibition were associated with a
reduced CRC risk, supporting findings from observational epidemiological studies that statins have
beneficial effect on the population burden of CRC.
Studies in mice have shown that knocking out the cell surface cholesterol-sensing receptor gene
NPC1L1, which plays a critical role in the absorption of intestinal cholesterol, reduces CRC risk31.
However, the biological mechanism by which cholesterol may affect CRC risk remains to be
established. Cholesterol is thought to have multiple carcinogenic/cancer promoting effects at the
cellular level and several mechanisms have been variously suggested, including the cholesterol-
mediated activation of the NLRP3 inflammasome32. Since statins are largely retained by
hepatocytes, their effect on CRC will be indirect, via HMGCR inhibition. Intriguingly, recent data
suggests that any impact of statin therapy on CRC is by prevention of progression of adenomas to
frank cancers rather than their development per se 33. Further research on the biological
relationship between cholesterol and CRC is needed to address such a proposition.
A major strength of our MR analysis is that it does not suffer from the influence of recall bias and
confounding that affects traditional observational studies. Nevertheless, a primary assumption in
MR is that the variants used to generate genetic scores are indeed associated with the exposure
being examined. To ensure this was the case, we only made use of variants associated with each
lipid trait at genome-wide significance from hypothesis-free GWAS. A second assumption is that
variants are associated with CRC only through the exposure and are not confounded by shared
genetic (i.e. pleiotropy). This would be revealed as an increasing linear relationship between SNPs
and their effect size for any lipid trait and CRC risk; we did not observe such a relationship.
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Although it is not possible to exclude confounding by unknown confounders, the use of multiple
independent variants acting through different pathways reduces the likelihood of confounded IV-
associations. Moreover by using LD regression, we have been able to exclude pleiotropism on a
global basis21. Finally, we only made use of data from individuals of European descent in the GWAS
SNPs to limit potential bias from population stratification influencing study findings.
As with any MR analysis, there are potential limitations to our findings, including the limited trait
variance explained by genetic variants, restricting statistical power. This is especially relevant for
null findings, since wide confidence intervals leave uncertainty over the presence of a causal
effect. It is estimated that the SNPs from the Global Lipids Genetics Consortium GWAS explain
approximately 8-11% of the total variation in each lipid trait19. Recent analyses of observational
studies found higher impact on CRC for TC than LDL or TG; respective ORs and 95% CIs – 1.49
(1.32-1.69), 1.37 (1.11-1.69), and 1.16 (1.06-1.27) 8. Based on these data our MR study was well-
powered to demonstrate a causal relation for TC (≈80%, stipulating a P-value of 0.05), but we had
limited power to identify associations for other lipid traits, particularly TG and HDL (respective
power estimates for TG, LDL and HDL being 13%, 68% and 31%). Hence while the ORs for CRC with
LDL and TG are congruous with observational studies 34 larger studies are required to formally
establish a relationship using MR.
There are differences in the genomic landscapes of colonic and rectal cancers which presumably
may reflect differences in aetiology. Unfortunately, these data were not uniformly collected across
datasets, and we therefore did not investigate the possibility of differential effects of cholesterol
on risk by anatomical location within the colorectum35.
In conclusion, this study provides evidence for a causal role of higher TC levels in the aetiology of
CRC. Hence our findings encouragingly support the overall findings of past observational studies.
Our limited power to further refine the relationship between lipid profile and CRC provides a
motivational for larger MR studies, which will benefit from enhanced statistical power to
demonstrate relationships for the spectrum of colorectal neoplasia. Irrespective of the exact
functional basis of the association between TC and CRC risk, reducing hyperlipidaemia is an
important target for primary prevention of CRC in the population. Our analysis therefore supports
the hypothesis that the increasing use of statins in the population for prevention of cardiovascular
disease will have the added bonus of reducing the burden of CRC.
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FIGURE LEGENDS
Figure 1: Meta-analysis odds ratios (OR) for colorectal cancer per unit increase in genetic risk
score (SD trait) for each lipid trait. TC: Total cholesterol, TG: Triglyceride, LDL: low density
lipoprotein, HDL: high density lipoprotein; Horizontal lines: 95% Confidence Intervals (95% CI). Phet:
P-value for heterogeneity; I2: proportion of the total variation due to heterogeneity. Box: OR point
estimate; its area is proportional to the weight of the study. Diamond: overall summary estimate,
with confidence interval given by its width. Vertical line: null value (OR = 1.0). 

Table 1: Summary of the seven genome-wide association studies of colorectal cancer (9,254 cases and 18,386)
Series Study setting Study centre Sampling No. cases No. controls
CCFR1 Colon Cancer Family Registry University of Southern California Recently diagnosed cases reported to population-based cancer
registries in the USA (Seattle Familial Colorectal Cancer
Registry). Canada (Ontario Familial Cancer Registry) and
Australia (Australasian Colorectal Cancer Family Study).
Population-based controls.
1,290 1,055
CCFR2 Colon Cancer Family Registry University of Southern California Recently diagnosed cases reported to population-based cancer
registries in the USA (Seattle Familial Colorectal Cancer Registry,
Mayo Clinic Cooperative Family Registry for Colon Cancer
Studies, USC Consortium Colorectal Cancer Family Registry,
University of Hawaii Colorectal Cancer Family Registry). Canada
(Ontario Familial Cancer Registry) Australia (Australasian
Colorectal Cancer Family Study). Unaffected family controls.
796 2,236
COIN COIN trial: Multicentre study of
cetuximab and other therapies in
metastatic CRC. Controls were
unselected blood donors
Cardiff University Cases recruited as a clinical-based series and controls as
population-based series.
2,244 2,162
FINLAND Finnish Colorectal Cancer
Predisposition Study
Helsinki University Cases requited through Finnish Hospitals and Finnish Cancer
Registry. Population-based controls from FINRISK, Health 2000,
Finnish Twin Cohort and Helsinki Birth Cohort Studies.
1,172 8,266
UK1 CORGI (colorectal Tumour Gene
Identification Consortium)
Oxford University Cases enriched for family history of CRC, ascertained through UK
clinical genetics clinics. Spouse controls with no personal history
or family history of CRC.
940 965
Scotland1 COGS (Colorectal Cancer
Susceptibility Study)
Edinburgh University Scottish population-based incidence cases aged <55 at diagnosis.
Population-based controls frequency matched by area of
residence. Scotland
1,012 1,012
VQ58 Cases: VICTOR, post treatment stager
of a phase III, randomised trial of
rofecoxib (VIOXX) in patients after
potentially curative therapy.
QUASAR2, multi-centre study of
capectibine±bevacizumb as adjuvant
treatment. 1958 Birth Cohort controls
Oxford University Cases recruited as a clinical-based series and controls as
population-based series.
1,800 2,690
Table 2: Testing for global and instrumental-specific pleiotropism. Point estimates, confidence
intervals, and P-values from linkage disequilibrium (LD) regression analysis, and MR-Egger
methods. For MR-Egger, the intercept represents the average pleiotropic effect; an intercept
significantly different from zero implies directional pleiotropy.
LD regression results
Trait Heritability estimate Genetic correlation Standard error P-value
TC 0.2408 0.049 0.0635 0.4402
TG 0.2939 0.0322 0.0639 0.6143
LDL 0.2122 0.0729 0.066 0.2696
HDL 0.2499 -0.0603 0.563 0.2834
MR-Egger regression results
Trait Estimate Correctedstandard error CI lower CI upper
P-value
TC intercept 1.11x10-2 1.25x10-2 -1.42x10-2 3.64x10-2 0.38
slope 0.16 0.33 -0.51 0.83 0.64
TG intercept -1.13x10-2 1.10x10-2 -3.38x10-2 1.12x10-2 0.31
slope 5.65x10-2 0.17 -0.30 0.42 0.75
LDL intercept -3.41x10-3 7.67x10-3 -1.91x10-2 1.23x10-2 0.66
slope 0.10 0.11 -0.11 0.32 0.34
HDL intercept 2.23x10-3 5.58x10-3 -8.94x10-3 1.34x10-2 0.69
slope -0.11 0.11 -0.32 0.11 0.31
